Carl Zeiss to acquire Acri.Tec

Carl Zeiss to acquire Acri.Tec

Carl Zeiss Meditec has announced that it intends to acquire Acri.Tec.

Acri.Tec generated sales revenues in the 2006 financial year of €15.4 million. The enterprise value calculated for the company totals €24 million and has to be reduced by the net financial debt at the closing date in order to determine the final purchase price.

B&L and Alcon settle dispute amicably

Bausch & Lomb and Alcon have settled a lawsuit that was filed recently regarding Alcon's promotional claims about Bausch & Lomb's ReNu MultiPlus solution.

Bausch & Lomb claimed that Alcon's promotional use of a chart to demonstrate the safety of contact lens solutions could negatively influence patients and/or doctors. The chart shows the safety of different solutions based on corneal staining tests, rating them with a colour coding system: green is safe, yellow means use with caution and red indicates the solution is unsafe. Bausch & Lomb alleged that the chart was produced without scientific studies or clinical evidence to back it up.

Alcon has agreed to change the red/yellow colour scheme and in light of this the lawsuit has been dismissed.

Alcon amends tender offer for Wavelight

Alcon has announced that it has amended its tender offer for Wavelight AG and waived the minimum tender offer acceptance threshold of 75% of all WaveLight outstanding shares.

The amendment extended the €15 per share offer to 25th September, 2007. Alcon now holds 70% of WaveLight shares through purchase, contractual commitment or tender.

Extending the offer period allows WaveLight shareholders to process the new information and take appropriate steps to tender their shares

Further, Carl Zeiss Meditec has announced it will not be launching a takeover bid for Wavelight. Zeiss had acquired a 5% shareholding in the firm to demonstrate its interest in a possible voluntary takeover but the company will now tender its share package to Alcon.